Azure Health Technology (AZT) Board Announcement 30/4/2020
The Board of Azure Health Technology (AZT) (“the Company”) is pleased to advise of the following developments following the withdrawal of the recent AZT Application for Requotation on the ASX (“Application”). These developments follow AZT receiving over 700 subscription applications for shares under a prospectus offer associated with the Application, from inside and outside of Australia, representing some $7.2mil at the time of the close of the offer.
We would like to thank you all who have participated and supported the offer.
Subsequent to the withdrawal of the Application:
The board members of AZT welcome and look forward to working with the Invictus Biopharma’s team. We hope that, by the joint force between the two companies, the new AZT can progress the development of its pipeline of drug candidates in the near future to benefit patients suffering from Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH) and pancreatic cancer. The new AZT, as an Innovative Enterprise, will advance its financing and capital raising activities. The Company will become one of a few companies that can make a difference to the welfare of our society through health technologies
The board would like to thank you again for your ongoing support to AZT.